Hematology/Oncology

Top Story

Selinexor regimen induces response in refractory multiple myeloma

August 21, 2019

A combination of selinexor and dexamethasone induced responses among patients with multiple myeloma refractory to current standard therapies, according to results of the phase 2b STORM study published in The New England Journal of Medicine.

The FDA granted the combination accelerated approval in July for treatment of relapsed or refractory multiple myeloma, based on the results of this study.

In the Journals

Exercise linked to longer PFS, fewer treatment-related toxicities in metastatic colorectal cancer

August 21, 2019

Patients with metastatic colorectal cancer who exercised regularly achieved longer PFS than those who did not, according to results of a companion study to the Cancer…

Feature

One health system’s experience relevant to looming price transparency rule

August 21, 2019

The Trump administration’s ongoing effort to lower health care costs and increase transparency resumes later this summer when HHS is expected to propose a rule…

In the Journals

Black, Hispanic populations underrepresented in trials supporting FDA cancer drug approvals

August 21, 2019

Landmark trials that led to FDA oncology drug approvals during the past decade frequently underrepresented black and Hispanic populations, according to results of a…

Feature

Annual screening may reduce breast cancer deaths by half among childhood cancer survivors

August 21, 2019

CHICAGO — Initiating annual breast cancer screening at a younger age may prevent more than half of all breast cancer-related deaths among childhood cancer…

More Headlines »

CME ABIM MOC